The document discusses opportunities for generics in Brazil and Latin America. It notes that generics have only 10% market share in Brazil currently. It outlines opportunities in key therapeutic areas as patents expire from 2007-2012. The company, Ambiance Ventures USA, offers services like contract manufacturing, private labeling, distribution and regulatory compliance to help clients capitalize on growth opportunities for generics in Brazil and other Latin American countries.